共 57 条
[1]
Shay DK(1999)Bronchiolitis-associated hospitalizations among US children, 1980-1996 JAMA 282 1440-1446
[2]
Holman RC(2012)Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006 Pediatr Infect Dis J 31 5-9
[3]
Newman RD(2002)Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999 Pediatr Infect Dis J 21 629-632
[4]
Liu LL(2009)The burden of respiratory syncytial virus infection in young children N Engl J Med 360 588-598
[5]
Stout JW(2015)Activity of oral ALS-008176 in a respiratory syncytial virus challenge study N Engl J Med 373 2048-2058
[6]
Anderson LJ(2003)Palivizumab prophylaxis reduces hospitalizations due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 143 532-540
[7]
Stockman LJ(1998)Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 102 531-537
[8]
Curns AT(2014)Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection Pediatrics 134 415-420
[9]
Anderson LJ(2010)Medical utilization associated with palivizumab compliance in a commercial and managed Medicaid health plan J Manag Care Pharm 16 23-31
[10]
Fischer-Langley G(2010)Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization J Manag Care Pharm 16 15-22